Inclusion Criteria:

- Patients with relapsed or refractory AML for which no standard therapies are
anticipated to result in durable remission. Or, patients with newly diagnosed AML
who are not considered to be suitable for standard induction and consolidation
chemotherapy

- Ability to stay in hospital for up to 9 days on the [14C] AZD1152 treatment cycle.

- Subjects who have relapsed > 1 year following myeloablative therapy with allogeneic
bone marrow or stem cell transplantation may be eligible if they have no or limited
evidence of extensive graft-versus-host disease

Exclusion Criteria:

- QTc interval ≥470 ms calculated from a single ECG reading or a mean of 3 ECG readings
using Fridericia's or Bazett's correction

- Administration of hydroxyurea to control peripheral blood counts is prohibited within
24 hours prior to first dose of study drug

- Any chemotherapy or radiotherapy within 14 days prior to starting the study (not
including palliative radiotherapy at focal sites)